Imugene (ASX: IMU) has decided to place the development of poultry vaccines on hold following a review of its activities.
The company undertook a review of its portfolio of vaccine products and intellectual property after the termination of a global licence agreement with Novartis in September 2011.
As a result of the review, Imugene plans to put its focus on components of its technology that have strong commercial prospects; in particular the company’s pig vaccines.
In addition, it is considering new approaches for delivering certain vaccines in order to maximise their efficacy.
Initially, Imugene will focus on new delivery approaches for the Porcine Reproductive and Respiratory Syndrome vaccine.
The company is involved in discussions with interested parties to gauge the level of commercial interest in progressing its technology.
In addition to putting its poultry vaccines on the back burner, Imugene plans to take a prudent approach to expenditure in 2012.